type 2 diabetes. Type 2 diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: 1 capsule of 500 mg of magnesium and 2 capsules of 500 mg of placebo per day for 60 days (Nano Kimia Health Co.). Intervention 2: Intervention group: 2 capsule of 5
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: patients with type 2 diabetes Men and women aged 60-30 years Patients who their diabetes have been controlled by glucose lowering tablets BMI=25-35 kg/m2
Exclusion criteria
Exclusion criteria: Unwillingness to cooperate patients with inflammatory diseases, allergy, MS, kidney, liver, thyroid diseases Use of insulin and corticosteroids and non-steroidal anti-inflammatory drugs and hormonal products Changes in diet and physical activity, and type or dosage of medications used during the study Pregnancy and breastfeeding Tobacco and supplement use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fast Blood Sugar. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Enzymatic with Commercial Kits.;Hemoglobin A1C. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA with Commercial Kits.;Insulin. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA.;Triglyceride. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Enzymatic.;Total Cholesterol. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Enzymatic.;HDL-Cholesterol. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Enzymatic.;LDL-Cholesterol. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Enzymatic.;Interleukin-6 (IL-6). Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA.;Vascular cell adhesion molecule 1 (VCAM-1). Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA.;Plasminogen activator inhibitor-1(PAI-1). Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA.;Tissue plasminogen activator(tPA). Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Pressure. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Digital Barometer.;Weight. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Scale.;Height. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: meter.;Body mass index(BMI). Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Computing.;Fat percent. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: Bio impedance set.;Waist circumference. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: meter.;Hip circumference. Timepoint: before the intervention and 60 days after the start of the intervention. Method of measurement: meter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Ali Tarighat Esfanjani
Tabriz University of Medical Sciences
Outcome results
None listed